Indian Journal of Pharmacology Home 

MOLECULES OF THE MILLENNIUM
[Download PDF]
Year : 2006  |  Volume : 38  |  Issue : 3  |  Page : 220--221

Rimonabant: A new class of drug to fight obesity

J Singh, S Budhiraja 
 Department of Pharmacology, Pt. B. D. Sharma PGIMS, Rohtak - 124001, Haryana, India

Correspondence Address:
S Budhiraja
Department of Pharmacology, Pt. B. D. Sharma PGIMS, Rohtak - 124001, Haryana
India




How to cite this article:
Singh J, Budhiraja S. Rimonabant: A new class of drug to fight obesity.Indian J Pharmacol 2006;38:220-221


How to cite this URL:
Singh J, Budhiraja S. Rimonabant: A new class of drug to fight obesity. Indian J Pharmacol [serial online] 2006 [cited 2021 Jan 20 ];38:220-221
Available from: https://www.ijp-online.com/text.asp?2006/38/3/220/25821


Full Text

Obesity and tobacco abuse, widely recognised as serious health hazards, are increasing in prevalence. Obesity is associated with numerous metabolic complications such as dyslipidemia, type 2 diabetes and cardiovascular diseases.[1] Smoking is a high risk factor for hypertension, lung carcinoma and various other health related problems.[2] The agents that have been used for the treatment of obesity include dexfenfluramine, phentermine, sibutramine and orlistat. Currently, the options for smoking cessation are nicotine patches, gum, lozenges and bupropion. As many of these drugs have serious adverse effects or are unsuitable for maintenance therapy, the search for a novel drug continues.

Rimonabant appears to be a promising drug in an entirely new class called selective cannabinoid (CB1) receptor antagonists. Recent studies have demonstrated the beneficial effects of rimonabant in tackling obesity, smoking cessation and metabolic syndrome. The drug may be approved for treatment of obesity and smoking cessation. Ongoing studies may provide information on its other clinical uses.

 Chemistry



Rimonabant (SR141716) is a neurokinin-3 antagonist and selective cannabinoid (CB1) receptor antagonist currently being researched and developed under the proprietary name, Acomplia, by Sanofi-Aventis. The chemical name is N-piperino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide.[3]

 Mechanism of action



Rimonabant is the first in a new class of agents that act by selectively blocking the cannabinoid-1 receptors with resultant central and metabolic peripheral effects, thereby decreasing food intake. Evidence currently exists for two types of cannabinoid receptors: CB1 and CB2. CB1 receptors are present both in the CNS as well as in certain peripheral tissues. The areas in which CB1 receptors are most dense are thought to deal with cognition, motor function and movement.[4] Rimonabant is reported to possess a 1000-fold higher affinity for the CB1 receptor than CB2 receptor. It shows high affinity for the centrally located cannabinoid receptor, while displaying low affinity for the peripherally located receptor. Additionally, it has little or no affinity for non-cannabinoid receptors.

 Pharmacokinetic parameters



Rimonabant has demonstrated a long duration of action (8 hours) and good oral bioavailability.[15] Currently, limited information has been published regarding rimonabant's pharmacokinetic parameters.

Functional in vitro and in vivo studies showed that rimonabant is able to antagonise the pharmacologic effects induced by cannabinoid receptor agonists.[5] It powerfully reduces food intake and increases energy expenditure. It modulates the rewarding properties of food by inhibiting the action of endogenous cannabinoids at specific mesolimbic areas. It alters the variety of signals of peripheral origin (leptin, ghrelin and adiponectin) which modulate the neurochemical activation of hypothalamic neurons and the state of relative energy balance. Rimonabant also inhibits the enzymes involved in lipogenesis.[6] Many rodent model studies have demonstrated a memory enhancing effect due to rimonabant use.[7] Certainly, more information will become available as the drug completes phase III trials.

 Preclinical trials



A number of preclinical trials have been conducted on the effects of rimonabant in rodent models. The trials demonstrated that rimonabant treatment was associated with a reduction in intake of highly palatable as well as normal foods in rats. Wiley et al [8] demonstrated that CB1 antagonist rimonabant dependently decreased food consumption at doses which did not affect motor activity in mice. These trials suggested that rimonabant may affect the actions of endogenous cannabinoids in regulating appetite or it may directly affect feeding behaviour. In another study, rodents were put on a high fat diet to develop obesity, increase energy intake and insulin resistance. During a five- week treatment period, rimonabant resulted in 48% reduction of food and 20% reduction in body weight. In addition, it helped in correcting insulin resistance.[9]

 Clinical trials



Some phase I/II clinical trials have been completed with rimonabant. However, limited information is available regarding these trails. A randomised, double blind, placebo-controlled crossover study assessed the effect of rimonabant on hunger, satiety, food consumption and body weight in obese humans and showed a reduction in their food intake and body weight.[10]

The results of phase III studies called RIO (Rimonabant in obesity)Europe, RIO-North America and RIO-Lipids, comparing rimonabant 5, 20 mg and placebo, have indicated significantly more weight loss with rimonabant. (The studies were prospective, randomised, international, multicentre, double blind, placebo-controlled trials.) The RIO-Lipids and RIO-Europe studies showed that the average loss of weight at 12 months was 6.9 and 8.6 kg, respectively, with rimonabant 20 mg/day; 3.1 and 4.8 kg, respectively, with rimonabant 5 mg/day.[11],[12] The RIO-North America trial was a two-year study that enrolled 3040 obese people throughout USA and Canada. The investigators found that those who received the highest dose of rimonabant (20 mg) lost >5% of their body weight, while one-third of them lost >10% of their body weight.[13] The results also showed an increase in HDL-C levels with a decrease in atherogenic LDL-C levels. The incidence of metabolic syndrome decreased by nearly one-third and insulin sensitivity was reported as greatly improved.

Rimonabant's role in smoking cessation will be evaluated in STRATUS-US, STRATUS-EU, STRATUS-WW (prospective, randomised, multicentre, double blind, placebo-controlled) trials.[14] Preliminary results of these trials showed that treatment with rimonabant greatly increases the likelihood of quitting smoking.

 Adverse effects



The results of early human trials with rimonabant treatment showed an excellent tolerance among patients, except for some mild gastrointestinal adverse effects at the highest dose administered. Safety data from the preliminary results of the RIO-Lipids, RIO-Europe, RIO-North America and STRATUS-US trials revealed that rimonabant is well tolerated among patients. The most frequently reported adverse effects are nausea, dizziness and upper respiratory infections. Diarrhoea was seen most commonly in the RIO-Europe trial (2.3%, 5.8% and 7% for placebo, rimonabant 5 mg/day and 20 mg/day, respectively).

 Advantages



l Rimonabant is reported to increase HDL-C and decrease atherogenic LDL-C levels. The unique property of this drug may, in turn, improve cardiovascular risk factors and metabolic syndrome.

l In addition to weight loss, rimonabant is reported to produce improvement in HbA 1c levels and may be helpful in diabetes.

l It also prevents weight gain in persons who are quitting smoking.

 Conclusion



Rimonabant, the selective blocker of CB1 receptors, may normalise the activity of the endocannabinoid system, resulting in weight loss, reduced waist circumference, improvement in lipid and glucose metabolism in obese people and may prevent weight gain associated with smoking cessation. The positive effects may, in turn, improve cardiovascular and metabolic risk factors. Future research and the results of ongoing clinical trials of this exciting drug are required to establish its long-term therapeutic implications.

References

1Bray GA, Bounchard C, James WPT, editors. Handbook of Obesity. New York: Marcel Dekker; 1998.
2Annual smoking attributable mortality, years of potential life lost and economic costs. United States 1995-1999.
3Iversen L. Cannabis and the brain. Brain 2003;126:1252-70.
4Howlett AC, Barth F, Bonner TI. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202.
5Compton DR, Aceto MD, Lowe J, Martin BR. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716): inhibition of delta-9-tetrahydro-cannabinol induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996;277:586-94.
6Cota D, Marsicano G, Tschop M. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Inves 2003;112:423-31.
7Coizet V, Cassel JC, Kelche C. Effects of the selective CB1 cannabinoid receptor antagonist, SR141716, on cognitive performance in intact, brain-damaged and scopolamine-treated rats. Behav Pharmacol 1998;9:25.
8Wiley JL, Burston JJ, Leggett DC. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 2005;145:293-300.
9Trillou CR, Arnone M, Delgorge C. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comjp Physiol 2003;284:345-53.
10Heshmati HM, Caplain H, Bellisle F. SR141716, a selective cannabinoid CB1 receptor antagonist, reduces hunger, caloric intake and body weight in overweight or obese men. Obes Res 2001;9:70.
11Van Gaal L. RIO-Europe: A randomized, double-blind study of weight reducing effect and safety of rimonabant in obese patients with or without comorbidity. Program and abstracts from the European Society of Cardiology Congress 2004, Aug 28-Sep1; Munich, Germany; 2004.
12Press release. [accessed 2004 Nov 9]. Available from: http://en.sanofi-aventis.com/press/p_press_2004.asp
13Results from the RIO-North America trial show that first year improvements in cardiovascular risk factors are maintained in the second year of treatment. American Society of Cardiology Congress, 2004 Nov 9 (online). [accessed 2005 Feb 10]. Available from: http://www.sanofi-synthelabo.us/index.html
14Boyd TS, Fremming BA. Rimonabant: a selective CB1 antagonist. Ann Pharmacother 2005;39:684-90.
15Rinaldi-Carmona M, Barth F, Heaulme M. Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 1995;56:1941-7.